Drivers and determinants of strain dynamics following fecal microbiota transplantation
- PMID: 36109636
- PMCID: PMC9499871
- DOI: 10.1038/s41591-022-01913-0
Drivers and determinants of strain dynamics following fecal microbiota transplantation
Abstract
Fecal microbiota transplantation (FMT) is a therapeutic intervention for inflammatory diseases of the gastrointestinal tract, but its clinical mode of action and subsequent microbiome dynamics remain poorly understood. Here we analyzed metagenomes from 316 FMTs, sampled pre and post intervention, for the treatment of ten different disease indications. We quantified strain-level dynamics of 1,089 microbial species, complemented by 47,548 newly constructed metagenome-assembled genomes. Donor strain colonization and recipient strain resilience were mostly independent of clinical outcomes, but accurately predictable using LASSO-regularized regression models that accounted for host, microbiome and procedural variables. Recipient factors and donor-recipient complementarity, encompassing entire microbial communities to individual strains, were the main determinants of strain population dynamics, providing insights into the underlying processes that shape the post-FMT gut microbiome. Applying an ecology-based framework to our findings indicated parameters that may inform the development of more effective, targeted microbiome therapies in the future, and suggested how patient stratification can be used to enhance donor microbiota colonization or the displacement of recipient microbes in clinical practice.
© 2022. The Author(s).
Conflict of interest statement
T.J.B. has a pecuniary interest in the Centre for Digestive Diseases in Australia and holds patents in the use of FMT for gastrointestinal diseases. C.Y.P. received funding grants from Gilead and Perspectum, speaker’s fees from Tillotts and consultancy fees from Shire and Pliant. M.N. and W.M.d.V. are founders and members of the Scientific Advisory Board of Caelus Health (the Netherlands). M.N. is a Scientific Advisory Board member of Kaleido Biosciences (USA). W.M.d.V. is founder and Scientific Advisory Board member of A-mansia Biotech (Belgium). These conflicts bear no relevance to the content of this manuscript.
Figures
Comment in
-
Understanding and predicting the efficacy of FMT.Nat Med. 2022 Sep;28(9):1759-1760. doi: 10.1038/s41591-022-01991-0. Nat Med. 2022. PMID: 36109641 No abstract available.
References
-
- Borody TJ, et al. Bacteriotherapy using fecal flora: toying with human motions. J. Clin. Gastroenterol. 2004;38:475–483. - PubMed
-
- Hanssen NMJ, de Vos WM, Nieuwdorp M. Fecal microbiota transplantation in human metabolic diseases: from a murky past to a bright future? Cell Metab. 2021;33:1098–1110. - PubMed
-
- Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin. Infect. Dis. 2011;53:994–1002. - PubMed
-
- van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N. Engl. J. Med. 2013;368:407–415. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
